DVA

Business profile & competitive position

DaVita Inc. operates in the Healthcare sector, specifically the Medical - Care Facilities industry, and is best known as one of the largest U.S. providers of kidney dialysis services for patients with chronic kidney failure and end-stage kidney disease. As of December 31, 2025, the company ran 2,657 outpatient U.S. dialysis centers serving approximately 200,500 patients, plus 585 international outpatient centers across 14 countries serving about 94,500 patients. Its service mix spans outpatient hemodialysis, hospital inpatient dialysis, home-based dialysis, kidney transplantation support, integrated kidney care, and ancillary laboratory services.

The economics of that footprint are reflected in the profitability numbers: a 6.0% net margin and a trailing P/E of 15.8. Those figures are consistent with a high-volume, regulated service business rather than a wide-moat, high-margin compounder. More striking is the -123.6% ROE, which signals that DaVita’s reported shareholders’ equity is negative even though the company is currently profitable. A negative book equity position is usually driven by large share repurchases, accumulated deficits, or a leveraged balance sheet; whatever the exact cause, it means the company’s accounting equity is deeply underwater, so the traditional ROE metric is not meaningful as a gauge of shareholder returns from equity capital.

Where a competitive advantage does show up is in scale and quality recognition. The 10-K notes DaVita has been an industry leader in CMS’s Quality Incentive Program for 11 of the most recently reported years and in the Five-Star Quality Rating System for 10 of those years. It also highlights that roughly 86% of consolidated revenue comes from U.S. dialysis, and that nearly all non-hospital dialysis profits come from commercial payors—not from government programs. That payer concentration is a structural reality, not a flaw: commercial reimbursement rates are materially higher than Medicare rates, so the profitability of the dialysis network depends heavily on maintaining commercial coverage for a sizeable share of the patient base.

Financial posture

DaVita currently commands an $11.8 billion market cap and trades at a P/E of 15.8. The net margin sits at 6.0%, which is neither razor-thin nor generous by broader market standards. A beta of 0.83 suggests the stock has historically moved a bit less violently than the overall equity market, which is plausible for a healthcare service provider whose revenue is tied to essential, recurring dialysis treatments.

The headline that jumps off the page is the ROE of -123.6%. When ROE is that negative, it tells us the denominator—book equity—is below zero. In other words, the firm’s liabilities exceed its accounting net assets, even as it posts positive net income. This is a common outcome after years of large share buybacks or when a company carries substantial debt against a small equity base. For analysis purposes it means investors should look through the ROE figure and focus on cash flows, debt service capacity, and the stability of the commercial payer book, because a textbook ROE-based valuation does not apply here.

Strategic priorities & outlook

The company’s most recent 10-K frames its strategy around reshaping how kidney care is delivered. DaVita says it wants to make care more preventative, better integrated, outcome-focused, lower-cost, and personalized at scale. A core operational priority is building integrated care capabilities across the renal care continuum, from chronic kidney disease through end-stage kidney disease and into kidney transplantation.

That integration effort is anchored in policy. DaVita is supporting CMS’s Comprehensive Kidney Care Contracting model goals, which are to delay disease progression, promote home dialysis when clinically appropriate, and incentivize transplants. The strategic emphasis on home-based options matters because home dialysis can lower per-treatment costs and, if adoption grows, could change the utilization profile of the clinic network over time. The international footprint—585 centers in 14 countries—is also part of the broader platform, though the 10-K makes clear that U.S. dialysis is still the dominant revenue engine at roughly 86% of consolidated revenue.

Macro & geopolitical exposure

Because DaVita is classified as a Medical - Care Facilities provider, its most direct macro exposures are regulatory and reimbursement-driven. Dialysis is heavily tied to Medicare and Medicaid, so any change to CMS reimbursement rates, bundled payment rules, or quality-based penalties can move the economics materially. The company’s participation in the Quality Incentive Program and the Five-Star Quality Rating System means that quality metrics are not just a public-relations issue; they directly affect reimbursement.

Commercial payor mix is another macro lever. The 10-K explicitly states that nearly all non-hospital dialysis profit comes from commercial payors, so trends in commercial insurance coverage, employer-sponsored plan generosity, and Medicare Advantage penetration all influence the bottom line. Labor costs are also significant; dialysis centers require trained clinical staff, and wage inflation or shortages of specialized nurses and technicians can pressure the already modest 6.0% net margin. Finally, the 14-country international footprint adds currency translation exposure and country-specific regulatory risk, even though international revenue is a smaller slice of the company.

Recent developments

The recent news flow has been eventful. On September 3, 2026, zacks.com published “Why Is DaVita HealthCare (DVA) Down 4.9% Since Last Earnings Report?,” capturing the post-earnings decline that followed the August 4 release. The same day, zacks.com also ran “Do Options Traders Know Something About DaVita Stock We Don’t?,” flagging unusual options activity without drawing conclusions. A few days earlier, on August 28, 2026, zacks.com placed DaVita inside a broader discussion of “4 Outpatient & Home Healthcare Stocks in Focus Amid Industry Tailwinds.” On August 27, 2026, fool.com reported that Warren Buffett and Greg Abel quietly hold a larger percentage of this company than any other in Berkshire Hathaway’s portfolio, an ownership concentration headline that has little to do with quarterly operations but can influence sentiment and liquidity.

None of these items give a clean directional signal on their own, but together they show a stock being discussed through three distinct lenses: post-earnings price action, options-market positioning, and ownership concentration by one of the market’s most-watched institutional holders.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, DaVita has beaten estimates six times, for a 75% beat rate, with an average earnings surprise of 2.3%. The average 5-day price move after earnings has been 6.36% to the upside, which the dataset classifies as an “up” drift. At first glance, that combination looks like a textbook post-earnings drift story, but the recent quarter-by-quarter history is far more nuanced.

On August 4, 2026, DaVita reported EPS of $4.02 against an estimate of $3.88, a 3.6% positive surprise. The stock nevertheless fell 17.24% the next day and 21.78% over the following five days. That single episode explains why the “beat = pop” assumption fails here. By contrast, the May 5, 2026 quarter was also a beat—actual EPS $2.87 versus estimate $2.41, or a 19.1% surprise—and the stock soared 23.46% the next session and 27.7% over the next five days. The February 2, 2026 quarter delivered a 4.9% beat ($3.40 vs. $3.24) and produced similarly strong moves of 21.17% next-day and 23.79% over five days. The one miss in this four-quarter window, on October 29, 2025, saw EPS of $2.51 versus an estimate of $3.17, a -20.8% miss that led to a -6.17% next-day drop and a -4.27% five-day drift.

Pattern hunters should note two things: the average post-earnings drift is heavily influenced by the two large positive reactions in early 2026, and even beat quarters can be met with sharp selling if the market’s real expectation is not just the reported estimate but also forward guidance, payer-mix trajectory, or regulatory clarity. The next scheduled report is October 28, 2026 after the close, with a consensus EPS estimate of $3.58.

For a deeper dive into how sell-side and institutional models are currently interpreting these dynamics, you can review the full institutional verdict on DVA, which consolidates analyst ratings, price-target ranges, and revision trends alongside the earnings history.